Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.2.2.22 extracted from

  • Vitetta, E.S.; Smallshaw, J.E.; Coleman, E.; Jafri, H.; Foster, C.; Munford, R.; Schindler, J.
    A pilot clinical trial of a recombinant ricin vaccine in normal humans (2006), Proc. Natl. Acad. Sci. USA, 103, 2268-2273.
    View publication on PubMedView publication on EuropePMC

Application

Application Comment Organism
medicine disruption of vascular leak syndrome-inducing site and of ribotoxic site. Injection i.m. into mice protects them against a ricin challenge of 10 LD50s. Injection into humans shows that the mutant is safe and elicits ricin-neutralizing antibodies in five of five individuals in the high-dose group Ricinus communis

Protein Variants

Protein Variants Comment Organism
V76M/Y80A disruption of vascular leak syndrome-inducing site and of ribotoxic site. Injection i.m. into mice protects them against a ricin challenge of 10 LD50s. Injection into humans shows that the mutant is safe and elicits ricin-neutralizing antibodies in five of five individuals in the high-dose group Ricinus communis

Organism

Organism UniProt Comment Textmining
Ricinus communis
-
-
-